REG - Oxford Biomedica PLC - Signs new agreement with AstraZeneca

Oxford BioMedicaAnnouncement

01/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220701:nRSA9213Qa&default-theme=true

RNS Number : 9213Q  Oxford Biomedica PLC  01 July 2022

 

The information contained within this announcement is deemed by the Group to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 (as it forms part of domestic law by virtue of the European
Union (Withdrawal) Act 2018). Upon the publication of this announcement via
the Regulatory Information Service, this inside information is now considered
to be in the public domain.

 

 

Oxford Biomedica signs new three year agreement with AstraZeneca

Oxford, UK - 1 July 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica"
or "the Company"), a leading gene and cell therapy group, today announces that
it has signed a new three year Master Services & Development Agreement
("the Agreement") with AstraZeneca UK Ltd ("AstraZeneca") which would
facilitate potential future manufacturing opportunities for the AstraZeneca
COVID-19 vaccine. This represents an expansion of the original Master Supply
and Development Agreement announced between the two companies in September
2020
(https://otp.investis.com/clients/uk/oxford_biomed1/rns/regulatory-story.aspx?cid=544&newsid=1410829)
.

 

The manufacture of COVID-19 vaccines at Oxford Biomedica's Oxbox facility is
expected to complete in the last quarter of 2022, as part of the original
commitment. In accordance with the terms of the original agreement and
inclusive of revenues for batches already manufactured in the first half of
2022, Oxford Biomedica expects to recognise aggregate revenues of
approximately £30 million from AstraZeneca in the current financial year.

 

Under the new agreement, manufacturing of vaccines at Oxford Biomedica's world
class 84,000 sq. ft manufacturing facility, Oxbox, will be available to
AstraZeneca on an as needed basis beyond 2022.

Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, commented: "I
am delighted that our close partnership with AstraZeneca has been extended. I
am proud of the work of all our colleagues at Oxford Biomedica that has
enabled us to deliver more than 100 million doses of lifesaving COVID-19
vaccine. While contributing to the efforts to fight the pandemic, this has
also demonstrated Oxford Biomedica's ability to expand the scope of our
innovative process development services and deliver high-performing
manufacturing solutions beyond lentiviral vectors. We look forward to
continuing to work closely with AstraZeneca and execute on our strategy to
become a global leader across all viral vectors, enabling Cell and Gene
Therapy companies to deliver their life-changing therapies to patients."

-Ends-

 

Enquiries:

 

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com

 

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

 

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 

Mary-Jane Elliott / Matthew Neal / Matthew Cole

 

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform,
which the Group leverages to develop product candidates in-house, before
seeking partners to take the products into clinical trials.

 

Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica
Solutions, a new US based subsidiary AAV manufacturing and innovation
business, based near Boston, US.

 

Oxford Biomedica employs more than 940 people. Further information is
available at www.oxb.com (http://www.oxb.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRBIGDLSSXDGDG